Ribo Life Science Submits European Clinical Trial Application for Novel Therapy

Suzhou Ribo Life Science and its Swedish subsidiary Ribocure Pharmaceuticals AB have submitted a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase 1 study. The application concerns RBD3133, a novel RNAi-based drug candidate developed by Ribo Life Science, designed to reduce the INHBE protein.

The drug candidate aims to treat a rare genetic disorder known as homocystinuria (HCU). HCU causes the accumulation of homocysteine in the body, potentially leading to serious health issues such as skeletal problems, blood clots, and cognitive impairment. Current treatment options are limited.

The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of RBD3133 in healthy volunteers at European research sites. If the study proceeds as planned, Ribo Life Science may advance to Phase 2 and Phase 3 trials subsequently.

Ribo Life Science focuses on developing novel RNA-based therapeutics. The company's listing on the Hong Kong Stock Exchange earlier this year has provided additional funding for its research and development efforts.